Shenyang Sunshine Pharmaceutical Co., LTD.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-30
RECRUITING5
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO0%
Delay Index: of 6 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Shenyang Sunshine Pharmaceutical Co., LTD. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Injection of humanized nerve growth factor (NGF) antibody NCT07008703 |
P1/2 | Recruiting | Cancer Pain | 132 | 2025-12 |
| SSS17 Capsule (6 Dose Levels) NCT07007936 |
P2 | Not yet recruiting | Postoperative Anemia; Arthroplasty, Replacement, Hip | 90 | 2026-04 |
| SSGJ-706 NCT07171606 |
P2 | Recruiting | First-line Advanced NSCLC Patients | 240 | 2026-08-31 |
| SSGJ-706+XELOX NCT07233850 |
P2 | Not yet recruiting | Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC) | 300 | 2026-12 |
| SSGJ-705 NCT07022002 |
P2 | Recruiting | Locally Advanced, Recurrent or Metastatic Malignancies | 340 | 2026-12-31 |
| SSGJ-705 NCT07646626 |
P2 | Recruiting | Locally Advanced (Unresectable) or Metastatic Solid Tumors | 150 | 2027-06-30 |
| SSGJ-706 NCT07874984 |
P2 | Not yet recruiting | Non Small Cell Lung Cancer | 220 | 2027-11 |
| SSS06 NCT06854276 |
P2 | Not yet recruiting | Chemotherapy-induced Anemia; Non-myeloid Malignancies | 80 | 2027-12-01 |
| SSGJ-612 (HER2-targeted antibody) NCT07757230 |
P2 | Recruiting | Metastatic Breast Cancer | 87 | 2028-02 |
| SPGL008 NCT07445308 |
P1/2 | Not yet recruiting | NMIBC | 120 | 2028-11-21 |